Abstracts tagged "Rheumatoid Factor"

Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
Abstract Number: 551 • 2015 ACR/ARHP Annual Meeting
Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
R Alten¹, HG Nüßlein², M Galeazzi³, H-M Lorenz⁴, X Mariette⁵, A Cantagrel⁶, M Chartier⁷, G Desachy⁸, C Poncet⁹, C Rauch¹⁰ and M Le Bars¹¹, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Erlangen, Nürnberg, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵Université Paris-Sud, Paris, France, ⁶Purpan Hospital, Toulouse, France, ⁷Chiltern International, Neuilly, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Docs International, Nanterre, France, ¹⁰Bristol-Myers Squibb, Munich, Germany, ¹¹Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In a recent meta-analysis, neither rheumatoid factor (RF) nor anti-cyclic citrullinated peptide (anti-CCP) antibody status were associated with clinical response to treatment with anti-TNF…
Abstract Number: 2676 • 2015 ACR/ARHP Annual Meeting
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Alejandro Garza-Alpirez¹, Mario Alberto Garza-Elizondo², David Vega-Morales², Cassandra Skinner-Taylor², Ricardo Ramírez³, Roberto Negrete-López⁴, Jorge Esquivel-Valerio², Miguel Villarreal-Alarcon² and Andrés Mendiola¹, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…
Abstract Number: 1207 • 2015 ACR/ARHP Annual Meeting
Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Miriam Gärtner, Mathias Schneeweiss, Josef S. Smolen and Klaus Machold, Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Antibody profiling encompassing rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) supports diagnosis in patients with Rheumatoid arthritis (RA). However, RF and ACPA are…
Abstract Number: 1559 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Medication Use Among Arab Patients with Rheumatoid Arthritis in Some Arab States
Karim Bayoumy¹, Soha Roger Dargham¹, Wessam Elhaq¹, Samar Al Emadi², Mohammed Hammoudeh², Basel Masri³, Hussein Halabi⁴, Humeira Badsha⁵, Imad Uthman⁶, Salah Mahdy², Robert Plenge⁷, Richa Saxena⁷, Marianthi Kapiri¹ and Thurayya Arayssi⁸, ¹Weill Cornell Medical College in Qatar, Doha, Qatar, ²Medicine, Hamad Medical Corporation, Doha, Qatar, ³Jordan Hospital, Amman, Jordan, ⁴Medicine, King Faisal Specialist Hospital and research center, Jeddah, Saudi Arabia, ⁵Al Biraa Arthritis and Bone Clinic, Dubai, United Arab Emirates, ⁶Internal Medicine, American University of Beirut, Beirut, Lebanon, ⁷The Broad Institute of MIT and Harvard, Program of Medical and Population Genetics, Cambridge, MA, ⁸Internal Medicine, Weill Cornell Medical College in Qatar, Doha, Qatar
Background/Purpose: Data on the clinical and genetic characteristics of Arab patients with Rheumatoid Arthritis (RA) is limited. Our aim is to report on the clinical…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…
Abstract Number: 407 • 2014 ACR/ARHP Annual Meeting
Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers
Olga Zhukov¹, Jonnielyn Rivera¹, Charles M. Rowland², Joanna M. Popov¹ and Stanley J. Naides³, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Bioinformatics, Celera, Alameda, CA, ³Immunology, Quest Diagnostics, San Juan Capistrano, CA
Background/Purpose: The 14-3-3 family of chaperonin proteins consists of 7 isomers. The tissue distribution of the 14-3-3η (eta) isoform is limited to synovial tissue and…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].